At the British Society of Gastroenterology Meeting in Glasgow, Scotland, investigators reported on the effectiveness of epidermal growth factor (EGF) enemas in the treatment of the condition.
Outpatients with active left-sided ulcerative colitis were enrolled in the randomized trial. Subjects either started on mesalazine 1.2g/day or had the dose increased by 1.2g/day. The patients self-administered enemas which contained either EGF (n = 8) or an inert carrier (n = 9) once a day for 2 weeks, and were reviewed at 2 and 4 weeks.
6 patients in the EGF group and 8 in the placebo group were on mesalazine before recruitment to the study.
|All parameters were significantly better in the EGF group at 2 and 4 weeks.
|British Society of Gastroenterology Annual Meeting |
2 patients from the placebo group developed worsening colitis and were withdrawn.
After 2 weeks of enema treatment, there were significant improvements in the EGF-treated group in symptom score, from median 3 to 1 (based on a score 0 or 1 for the absence or presence of liquid stools, nocturnal diarrhea, and visible blood in stools).
There were also improvements in incidence of diarrhea from median 5 to 2 motions per 24 hours, sigmoidoscopic score from median 2.5 to 1, and histological score, from median 3 to 2. No significant change in these parameters was seen in the placebo group.
All parameters measured were significantly better in the EGF group than in the placebo group at 2 and 4 weeks.
Researcher A. Sinha and colleagues found that 7 out of the 8 patients in the EGF group, as compared to none in the placebo group, achieved remission after 2 weeks. At 4 weeks, 6 patients in the EGF group and 1 in the placebo group were in remission.
The authors concluded that EGF enema is an effective treatment for left-sided ulcerative colitis, and that a dose increase of 1.2g mesalazine had little effect on colitis activity.